Abstract

Background The purpose of this study was to examine the benefits of inositol-stabilized arginine silicate (ASI; Nitrosigine) as a workout ingredient in healthy adults. ASI has been previously shown to significantly enhance blood levels of arginine up to six hours post-dose and increase nitric oxide levels. To investigate reports of enhanced energy, increased muscle pump and stamina during workouts, and faster muscle recovery post-workout, ASI (1,500mg/ day) was tested in a double-blind placebo-controlled crossover-design (DBPC-X) study using the POMS vigor-activity and fatigue-inertia sub-scores, blood flow measurements, leg circumference measurements, and biomarkers of muscle recovery (creatine kinase (CK) and lactate dehydrogenase (LDH)) as outcome measures.

Highlights

  • The purpose of this study was to examine the benefits of inositol-stabilized arginine silicate (ASI; Nitrosigine®) as a workout ingredient in healthy adults

  • CK levels significantly decreased in the ASI group at 24 (p = 0.040), 48 (p = 0.017) and 72 (p = 0.034) hours postexercise compared to the placebo group

  • LDH levels significantly increased from baseline immediately after exercise in the placebo group (p = 0.015), but not in the ASI group (p = 0.366); p = 0.133 between groups

Read more

Summary

Introduction

The purpose of this study was to examine the benefits of inositol-stabilized arginine silicate (ASI; Nitrosigine®) as a workout ingredient in healthy adults. ASI has been previously shown to significantly enhance blood levels of arginine up to six hours post-dose and increase nitric oxide levels. To investigate reports of enhanced energy, increased muscle pump and stamina during workouts, and faster muscle recovery post-workout, ASI (1,500mg/ day) was tested in a double-blind placebo-controlled crossover-design (DBPC-X) study using the POMS vigor-activity and fatigue-inertia sub-scores, blood flow measurements, leg circumference measurements, and biomarkers of muscle recovery (creatine kinase (CK) and lactate dehydrogenase (LDH)) as outcome measures

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.